
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+2
Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The companys highly differentiated clinical-stage pipeline has multiple candidates with best-in-class potential. The lead asset IMG-007, a non-depleting anti-OX40 mAb, is in two global Phase 2a clinical trials in atopic dermatitis and alopecia areata. IMG-004, a non-covalent reversible BTK inhibitor is in a Phase 1 multiple ascending dose (MAD) study. IMG-008, an in-house developed long-acting anti-IL-36R mAb is entering global Phase 1 clinical development
Immunology ,inflammation,biotechnology,ox40,btk,il-36r,and i&i
Inmagene biopharmaceuticals operates in the Biotechnology research industry.
Inmagene biopharmaceuticals's revenue is 11m - 100m
Inmagene biopharmaceuticals has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.